– USA, MA – CoLucid Pharmaceuticals, Inc. (Nasdaq:CLCD), a Phase 3 clinical-stage biopharmaceutical company that is developing its lead product candidate, lasmiditan, for the acute treatment of migraine headaches, announced today the appointment of Marvin L. White to its Board of Directors and as Chairman of the Audit Committee. CoLucid’s Board now stands at seven directors, six of whom are independent.
Mr. White serves as the president and chief executive officer of The MLW Advisory Group, LLC, a management advisory company targeting the needs of healthcare and related companies. From 2008 to 2014, Mr. White served as system vice president and chief financial officer of St. Vincent Health, and was responsible for finance, accounting, patient financial services and managed care for 19 hospitals and 36 joint ventures. Prior to joining St. Vincent Health in 2008, Mr. White was executive director and chief financial officer of Lilly USA, a subsidiary of Eli Lilly and Company, where he also held leadership positions in Corporate Finance and Investment Banking in the Corporate Strategy Group. He also serves on the boards of Emergent Biosolutions, OneAmerica Financial Partners and WP Glimcher.
“We are thrilled to have Marvin join our board, especially given his SEC financial technical expertise and big Pharma experience as a CFO of a $7 billion pharmaceutical company’s U.S. subsidiary. Beyond that, Marvin brings significant large hospital system experience that provides him with deep insight into provider access and reimbursement practices, as well as the impact of the Affordable Care Act,” commented Thomas P. Mathers, Chief Executive Officer of CoLucid.
About CoLucid Pharmaceuticals, Inc.
CoLucid was founded in 2005 and is developing oral lasmiditan for the acute treatment of migraine headaches in adults and intravenous lasmiditan for the acute treatment of unspecified headache pain in adults in emergency room and other urgent care settings.
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
